Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Schultz-Fademrecht

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Oncotarget|June 22, 2016
Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeuticsJeffery Chakedis, Randall French, Michele Babicky, et al.
Nature Communications|September 7, 2021
Cellular model system to dissect the isoform-selectivity of Akt inhibitorsLena Quambusch, Laura Depta, Ina Landel, et al.
Journal of Medicinal Chemistry|October 31, 2009
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumorsPhilip Jones, Sergio Altamura, Julia Boueres, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the seriesArthur Oubrie, Allard Kaptein, Edwin de Zwart, et al.
Nature Communications|April 21, 2016
Identification of pyrazolopyridazinones as PDEδ inhibitorsBjörn Papke, Sandip Murarka, Holger A Vogel, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2011
Structure-based lead identification of ATP-competitive MK2 inhibitorsTjeerd Barf, Allard Kaptein, Sander de Wilde, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2011
Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitorsAllard Kaptein, Arthur Oubrie, Edwin de Zwart, et al.
Nature|February 21, 2014
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cellsMagdalena Paolino, Axel Choidas, Stephanie Wallner, et al.
Chemmedchem|September 30, 2017
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerUlrich Lücking, Arne Scholz, Philip Lienau, et al.
Journal of Medicinal Chemistry|April 29, 2022
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsJonas Lategahn, Hannah L Tumbrink, Carsten Schultz-Fademrecht, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Oncotarget|June 22, 2016
Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeuticsJeffery Chakedis, Randall French, Michele Babicky, et al.
Nature Communications|September 7, 2021
Cellular model system to dissect the isoform-selectivity of Akt inhibitorsLena Quambusch, Laura Depta, Ina Landel, et al.
Journal of Medicinal Chemistry|October 31, 2009
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumorsPhilip Jones, Sergio Altamura, Julia Boueres, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the seriesArthur Oubrie, Allard Kaptein, Edwin de Zwart, et al.
Nature Communications|April 21, 2016
Identification of pyrazolopyridazinones as PDEδ inhibitorsBjörn Papke, Sandip Murarka, Holger A Vogel, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2011
Structure-based lead identification of ATP-competitive MK2 inhibitorsTjeerd Barf, Allard Kaptein, Sander de Wilde, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2011
Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitorsAllard Kaptein, Arthur Oubrie, Edwin de Zwart, et al.
Nature|February 21, 2014
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cellsMagdalena Paolino, Axel Choidas, Stephanie Wallner, et al.
Chemmedchem|September 30, 2017
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerUlrich Lücking, Arne Scholz, Philip Lienau, et al.
Journal of Medicinal Chemistry|April 29, 2022
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsJonas Lategahn, Hannah L Tumbrink, Carsten Schultz-Fademrecht, et al.
Pageof 4